The clinical data of NLRP3 inhibitors are impressive, and the treatment of cardiovascular diseases is ushering in a "renaissance moment" (Goldman Sachs)
Goldman Sachs pointed out in its global healthcare report that NLRP3 inhibitors have shown great potential in the treatment of cardiovascular diseases, especially in the Phase 2 ZEUS trial.
Goldman Sachs pointed out in its global healthcare report that NLRP3 inhibitors have shown great potential in the treatment of cardiovascular diseases, especially in the Phase 2 ZEUS trial. BGE-102 achieved up to 86% reduction in hsCRP levels in the 60 mg and 120 mg dose groups, and most patients reached normal levels within a week. This proves that this mechanism can quickly and effectively inhibit key inflammatory pathways, providing new treatment ideas for cardiovascular diseases such as atherosclerosis. Compared with the market's previous doubts about the druggability of NLRP3 target, these data establish its clinical feasibility and may open up a huge new market. One-sentence conclusion: The early clinical data of NLRP3 inhibitors far exceeded expectations, marking the arrival of an era of anti-inflammatory treatment for cardiovascular diseases. Related biotech companies are facing huge opportunities to reshape their valuations. Positive/negative: Positive for biotech companies with NLRP3 inhibitors such as BIOA (BGE-102), VTYX (VTX3232), and GLUE (MRT-8102). The market's attention to this field is increasing, but there is still some time before commercialization. At present, it is more thematic investment. Catalysts: 1) Phase 2 PoC results from BIOA (expected before year-end); 2) Combination therapy data with NLRP3 inhibitors and GLP-1 drugs; 3) Primary cardiovascular endpoint results from the Phase 3 ZEUS trial, which are decisive valuation catalysts.